Novel tumor-specific antigens for myeloid leukemia and uses thereof
AssigneeUniversite de Montreal
InventorsClaude PERREAULT, Pierre THIBAULT, Marie-Pierre HARDY
Life of this patent
Estimating the term…
Abstract
Acute myeloid leukemia (AML) has not benefited from innovative immunotherapies, mainly because of the lack of actionable immune targets. Novel tumor-specific antigens (TSAs) shared by a large proportion of AML cells are described herein. Most of the TSAs described herein derives from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells and vaccines derived from these TSAs are described. The use of the TSAs, nucleic acids, compositions, cells and vaccines for the treatment of myelodysplastic syndrome (MDS) or leukemia such as AML is also described.
Claims17
1-59. (canceled)
A method of treating myelodysplastic syndrome (MDS) or leukemia in a subject comprising administering to the subject an effective amount of:
- (a) a tumor antigen peptide (TAP) comprising or consisting of any one of the sequences set forth in SEQ ID NOs:
- 1-11 or any combination thereof, or a synthetic long peptide (SLP) comprising at least one of the sequences set forth in SEQ ID NOs:
- 1-11;
- (b) at least one nucleic acid encoding the TAP, combination thereof or SLP defined in (a);
- (c) a vesicle or particle comprising the TAP, combination thereof or SLP defined in (a) or the at least one nucleic acid defined in (b);
- (d) a composition comprising the TAP, combination thereof or SLP defined in (a), the at least one nucleic acid defined in (b), or the vesicle or particle defined in (c), and a pharmaceutically acceptable carrier;
- (e) a vaccine comprising the TAP, combination thereof or SLP defined in (a), the at least one nucleic acid defined in (b), the vesicle or particle defined in (c), or the composition defined in (d), and an adjuvant;
- (f) a cell expressing at its surface major histocompatibility complex (MHC) class I molecules comprising the TAP or combination thereof defined in (a) in their peptide binding groove;
- (g) a cell expressing at its cell surface a T-cell receptor (TCR) that specifically recognizes MHC class I molecules expressed at the surface of the cell defined in (f);
- or
- (h) a soluble TCR, an antibody or an antigen-binding fragment thereof that specifically binds to the MHC class I molecules expressed at the surface of the cell defined in (f).
A vaccine comprising:
- (a) (i) a tumor antigen peptide (TAP) comprising or consisting of any one of the sequences set forth in SEQ ID NOs:
- 1-11 or any combination thereof, a synthetic long peptide (SLP) comprising at least one of the sequences set forth in SEQ ID NOs:
- 1-11, or (ii) at least one nucleic acid encoding the TAP, combination thereof or SLP defined in (i);
- and
- (b) at least one vaccine adjuvant.
Dependencies are inferred from the claim text.